Gland Pharma’s Board of Directors convened on June 15, 2026, approving key personnel changes. Mr. Udo Jahannes Vetter was re-appointed as Independent Director for a second five-year term. Mr. William Robert Keller was appointed as an Additional Director. Mr. Satyanarayana Murthy Chavali resigned as Independent Director due to potential conflicts of interest. The board committees were also realigned following these changes.
Key Board Decisions at Gland Pharma
On June 15, 2026, the Board of Directors of Gland Pharma Limited held a significant meeting where several important decisions regarding directorial appointments and re-appointments were made. These changes aim to strengthen the company’s governance and strategic direction.
Director Re-appointment and New Appointment
The Board approved the re-appointment of Mr. Udo Jahannes Vetter (DIN: 00707474) as an Independent Director for a second consecutive term of five years. This re-appointment is effective from July 21, 2026, to July 20, 2031. Shareholders’ approval for this re-appointment will be sought via postal ballot and e-voting within the stipulated timelines.
Furthermore, Mr. William Robert Keller (DIN: 11593622) has been appointed as an Additional Director (Non-Executive – Independent Director) to the Board, effective June 15, 2026. Mr. Keller brings extensive global experience in the pharmaceutical and biotechnology sectors. His appointment also requires shareholder approval through postal ballot and e-voting.
Resignation of Independent Director
Mr. Satyanarayana Murthy Chavali, an Independent Director, has tendered his resignation from the Board. This decision was driven by a potential conflict of interest arising from his involvement as a Promoter and Director in another company that plans to enter a business segment similar to or overlapping with Gland Pharma’s proposed business activities. His resignation is effective from the close of business hours on June 15, 2026. The company expressed its deep appreciation for Mr. Murthy’s long-standing leadership and contributions.
Subsidiary and Committee Realignments
Consequent to Mr. C.S.N. Murthy’s resignation, Mr. Essaji Goolam Vahanvati, an Independent Director, has been appointed as a Director on the Board of Gland Pharma International Pte. Ltd, the company’s material subsidiary, effective June 15, 2026. The list of directors for this subsidiary after reconstitution has been provided.
In light of these changes, the Committees of the Board have also been realigned, effective June 15, 2026, in compliance with the Listing Regulations. Details of the committee compositions as of June 15, 2026, including the changes made, are enclosed.
Meeting Details
The Board meeting commenced at 15:00 Hrs. IST and concluded at 15:50 Hrs. IST on June 15, 2026.
Source: BSE
